Physician profile
Donald E Paxton
NPI 1952343824
$1,547.67
in general payments reported to CMS, 2019-2025
17 companies · $193 in 2025
The $193 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $269 · 2021: $164 · 2022: $153 · 2023: $59.15 · 2024: $378 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $598 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $597.56 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $310.60 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $279.11 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $234.72 | 2021-2025 | Airsupra, Breztri |
| Biohaven Pharmaceuticals, INC. | $187.99 | 2020-2021 | |
| Genentech USA, INC. | $148.69 | 2019 | |
| Abbott Laboratories | $108.76 | 2022-2025 | Freestyle Libre 3 |
| Pfizer INC. | $67.09 | 2020-2025 | |
| Glaxosmithkline, LLC. | $46.16 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $33.85 | 2019-2025 | Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $22.18 | 2019 | |
| Harmony Biosciences LLC | $21.90 | 2024 | |
| Daiichi Sankyo INC. | $20.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.85 | 2022 | |
| Sanofi Pasteur INC. | $13.42 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.20 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $13.11 | 2024 | Cologuard Collection Kit |
| Phadia US INC. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Paxton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.